- Discuss the history and properties of MSCs
- Discuss rationale for use of uMSC in COVID-19
- Present institutional Protocol for use of uMSC in COVID-19 pneumonia
- Present local experience and outcome of patients treated with uMSC with COVID-19
Keywords: MSCs, uMSC, COVID-19, pneumonia.
Vasiliki E. Kalodimou is the Collaborative partner for training and research for Regenerative Medicine Program at the Institute of Personalized Molecular Medicine at the Medical City Hospital, Philippines, the Board/Committee on Research Ethics at the National Hellenic Research Foundation, the Vice-Chair of the UEL Alumni Advisory Board, previously was the Director at the Flow Cytometry-Research and Regenerative Medicine Department of IASO in Greece, as well as the CBB & Processing Facility Director at MedStem-Cryobanks. In addition to collaboration with state universities and pharmaceutical companies on research projects (17), frequently publishes (46 & 9 books) her findings. She has 2 patents.